CureVac starts Phase IIb trial of CV9104

A German company called CureVac GmbH has started Phase IIb clinical trials of another cancer “vaccine” for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

CureVac ready to take CV9103 into Phase IIb clinical trials

According to a story yesterday on the FierceBiotech web site, a German multibillionaire is investing > $100 million into a company called CureVac that has a new prostate cancer “vaccine” ready for Phase IIb clinical trials. … READ MORE …